{"id": "chatcmpl-8JYR7qHKFMCuzWE0atQb3iQKvgbYs", "object": "chat.completion", "created": 1699671297, "model": "gpt-4-0613", "choices": [{"index": 0, "message": {"role": "assistant", "content": "1. Low\u2010density lipoprotein cholesterol (LDL\u2010C), PCSK9, and alirocumab levels were assessed in subjects.\n2. The subjects had LDL\u2010C levels greater than 130 mg/dL.\n3. There were 24 subjects in each group.\n4. The subjects underwent a 4\u2010week run\u2010in.\n5. During the run-in, subjects were taking oral ezetimibe, fenofibrate, or ezetimibe placebo.\n6. Alirocumab 150 mg was added every 4 weeks.\n7. Alirocumab was added on days 1, 29, and 57."}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 125, "completion_tokens": 135, "total_tokens": 260}, "temperature": 0, "max_tokens": 512, "top_p": 1, "frequency_penalty": 0, "presence_penalty": 0, "messages": [{"role": "system", "content": "Statement: Low\u2010density lipoprotein cholesterol (LDL\u2010C), PCSK9, and alirocumab levels were assessed in subjects (LDL\u2010C >130 mg/dL, n=24/group) after a 4\u2010week run\u2010in taking oral ezetimibe, fenofibrate, or ezetimibe placebo, when alirocumab 150 mg every 4 weeks (days 1, 29, and 57) was added.\n\nList all the facts we explicitly know from the statement. Make each fact as atomic as possible."}]}